Key Points
-
10,000 shares were sold for approximately $350,000 at a weighted average price of $35.01 per share on June 22, 2026.
-
The sale represented 7.15% of Mark Schoenberg’s direct holdings, reducing his position from 139,763 to 129,763 shares.
-
The transaction involved only directly held common stock with no derivative securities or indirect holdings.
-
Schoenberg retains 129,763 direct shares following the transaction.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (NASDAQ:URGN) reported the sale of 10,000 shares of common stock in an open-market transaction on June 22, 2026, according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 10,000 |
| Transaction value | $350,100 |
| Post-transaction shares (direct) | 129,763 |
| Post-transaction value (direct ownership) | ~$4.54 million |
Transaction value based on SEC Form 4 weighted average purchase price ($35.01); post-transaction value based on June 22, 2026, market close ($34.99).
Key questions
- How does this sale compare to Schoenberg’s historical trading activity?
The 10,000-share sale aligns with his typical open-market trading pattern, with recent sell-only transactions averaging around 9,000 shares over the past year. - What impact does this have on his ownership stake?
The transaction reduced Schoenberg’s direct holdings by 7.15%, though he continues to maintain a significant ownership position of 129,763 ordinary shares. - Were any derivative securities or indirect holdings involved?
No derivative instruments or indirect entities were involved; the sale consisted exclusively of directly held common stock. - What does the cadence of recent trades indicate about Schoenberg’s strategy?
Regular 10b5-1 plan-driven sales with a declining total share base suggest routine liquidity management rather than a reduction in long-term conviction.
Company overview
| Metric | Value |
|---|---|
| Stock price (as of market close 6/22/26) | $35.01 |
| Market capitalization | $1.8 billion |
| Revenue (TTM) | $140.49 million |
| 1-year price change | 174.3% |
* 1-year performance calculated using June 30, 2026, as the reference date.
Company snapshot
- Develops and commercializes specialty therapeutics for urothelial and other specialty cancers, with key products including Jelmyto and Zusduri, and a pipeline focused on non-muscle-invasive bladder and upper tract urothelial cancers.
- Operates a biotechnology model centered on proprietary drug formulations and sustained-release delivery platforms, generating revenue primarily from product sales and licensing agreements.
- Targets urology specialists, oncologists, and healthcare providers treating patients with non-muscle invasive urothelial cancers in the United States.
UroGen Pharma Ltd. is a biotechnology company specializing in innovative therapies for urothelial cancers, leveraging proprietary hydrogel technology and sustained-release drug formulations. The company’s strategy emphasizes advancing late-stage clinical candidates and expanding its commercial footprint in niche oncology markets. UroGen’s competitive edge lies in its differentiated delivery platforms and focus on unmet medical needs within urologic oncology.
What this transaction means for investors
Schoenberg’s recent sale of UroGen stock appears consistent with routine personal financial planning rather than a signal of diminished confidence in the company’s prospects. He maintained the substantial majority of his shares following the transaction.
The company is advancing UGN-103, a potential new treatment option for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The candidate shares similarities with the already commercialized Zusduri but offers streamlined manufacturing and reconstitution processes. Clinical data showed results comparable to those supporting Zusduri’s regulatory approval and market performance.
In the first quarter of 2026, Zusduri sales reached $29.2 million, up significantly from $15.8 million in the fourth quarter of 2025. The company expects Jelmyto sales for upper tract bladder cancer to range between $97 million and $101 million in 2026, compared to $94 million in 2025.
While UroGen continues to report operating losses, the magnitude has been decreasing. First-quarter 2026 losses totaled $23.6 million, compared to $43.8 million in the same period of the prior year.
